Biopharma new product strategic launch sequencing (SLS) is becoming increasingly more controversial and complex. In the first part of this article on biopharma new product SLS, we review the background and significant challenges the Biopharma industry faces in new product launch sequencing. In the second part, we discuss likely ramifications associated with delays in Biopharma drug launches, how modern new product SLS needs to evolve, and some of the factors that it must now consider.